|
|
|
|
|
|
|
||
Original Article |
B–Dependent Gene Activation in Islets
cferran{at}caregroup.harvard.edu
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
–induced apoptosis. The cytoprotective effect of A20 against apoptosis correlates with and is dependent on the abrogation of cytokine-induced NO production. The inhibitory effect of A20 on cytokine-stimulated NO production is due to transcriptional blockade of inducible NO synthase (iNOS) induction; A20 inhibits the activation of the transcription factor nuclear factor 
B at a level upstream of IB
degradation. These data demonstrate a dual antiapoptotic and antiinflammatory function for A20 in β cells. This qualifies A20 as part of the physiological cytoprotective response of islets. We propose that A20 may have therapeutic potential as a gene therapy candidate to achieve successful islet transplantation and the cure of IDDM.
Key Words: A20 • β cells • nuclear factor B • nitric oxide • apoptosis
Type I insulin-dependent diabetes mellitus (IDDM)1 is an autoimmune disease resulting from specific destruction of the insulin-producing β cell within the islet of Langerhans 12. Many studies have focused on the initiator phase of the disease, exploring the factors that permit or provoke the autoimmune attack 234. More recently, greater attention has been devoted to understanding the mechanisms of β cell susceptibility to death. Although multiple mechanisms are involved in the destruction of β cells, the common unifying theme remains that most of these trigger the apoptotic machinery of the β cell 56.
β cell apoptosis can be induced by either specific T lymphocyte–mediated killing or proinflammatory cytokines. T cell–mediated β cell damage occurs through direct cognate interactions using the granzyme/perforin or Fas/Fas ligand (FasL) systems 78. Cytokine-mediated β cell apoptosis requires the active participation of the β cells. The intraislet release of IL-1β, TNF-
Since the early work of Reckard et al. 17 and Ballinger 18 showing that islet transplantation could cure diabetes in rodents, islet transplantation for humans has been regarded as a potential cure for diabetes 17181920. However, several obstacles still need to be overcome before successful islet transplantation becomes a reality, namely, (a) primary nonfunction in the immediate posttransplantation period, (b) recurrence of autoimmune disease, and (c) allograft rejection 212223. Whether related to hypoxia, loss of nutrients, induction of nonspecific inflammatory reactions, or immune effectors implicated in the development of autoimmune disease or allograft rejection, the final outcome of these processes is destruction of the transplanted islets by apoptosis.
One way to achieve successful islet transplantation for the treatment of IDDM would be to genetically engineer β cells to express antiapoptotic and antiinflammatory proteins 24. The zinc finger protein A20 represents one such candidate for genetic engineering of β cells. A20 was originally described as an antiapoptotic TNF-
Analysis of A20 mRNA Expression in Islets.
rAd Vectors and Gene Transduction of Rodent Islets.
Analysis of A20 Protein Expression and Islet Viability after rAd Infection.
Flow Cytometric Analysis of Apoptosis.
Determination of iNOS Protein Expression.
Determination of NO (Nitrite) Generation.
Analysis of the Role of NO in Cytokine-induced Apoptosis.
Transient Transfection of the Murine β Cell Line, β-TC3.
Electrophoretic Mobility Shift Assay.
Determination of I
Statistical Analysis., and IFN- by activated mononuclear cells activates β cells to upregulate inducible nitric oxide synthase (iNOS) 910. Generation of iNOS results in the production of high levels of nitric oxide (NO) and, to a lesser extent, superoxide 1112. NO and its reactive oxygen species derivatives, including peroxynitrite (OONO–), are cytotoxic to β cells 1314. NO-mediated toxicity is the predominant mechanism responsible for β cell dysfunction and apoptosis induced by soluble mediators. In addition to its direct toxic potential, NO induces Fas expression on β cells, priming them to T lymphocyte–mediated killing 15. The central role played by NO in the pathophysiology of β cell loss during IDDM is directly demonstrated by the acceleration of IDDM in nonobese diabetic (NOD) mice (a well-studied experimental model of autoimmune diabetes) carrying the inos transgene under the control of the insulin promoter 16. –induced gene in endothelial cells 2526. Besides protection from apoptosis, we have demonstrated previously that A20 also inhibits proinflammatory responses in endothelial cells 2728. In this paper, we evaluate the efficacy of A20 to protect islets from apoptosis. We demonstrate that recombinant adenovirus (rAd)-mediated gene expression of A20 in rodent islets protects against cytokine-induced apoptosis and inhibits cytokine-induced NO generation. A20 suppresses cytokine-induced NO generation at the level of iNOS transcription through blockade of the transcription factor, nuclear factor B (NF-B). Furthermore, we report for the first time that A20 mRNA is rapidly induced in human and rat islets after cytokine stimulation. These later data indicate that A20 is part of the physiological protective response of islets, further supporting its consideration for human gene therapy.
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Islets.
Rats (male Sprague-Dawley) were purchased from The Jackson Laboratory, and islets were isolated as described previously 23. Human islets were a gift from Dr. C. Ricordi (Diabetes Research Institute, University of Miami School of Medicine, Miami, FL). Both rodent and human islets were cultured in RPMI 1640, 10% FCS with 2 mM L-glutamine, 5 mM D-glucose, and 50 U/ml of penicillin and streptomycin, at 37°C with 5% CO2.
Total mRNA was isolated from human and rodent islets (RNeasy Mini Protocol; Qiagen), and cDNA was synthesized using random hexamers (Superscript Preamplification System for First Strand cDNA Synthesis; GIBCO BRL). PCR reactions were performed with the following primers: rodent β-actin: sense, 5'-CCTGACCGAGCGTGGCTACAGC-3', and antisense, 5'-AGCCTCAGGGCATCGGAAC-3'; A20: sense, 5'-TTTGAGCAATATGCGGAAAGC-3', and antisense, 5'-AGTTGTCCCATTCGTCATTCC-3'; rat iNOS: sense, 5'-TGACCTGAAAGAGGAAAAGGAC-3', and antisense, 5'-CCAGTTTTTGATCCTCACGTG-3'. The PCR reaction was optimized for each primer pair. PCR was performed over a range of cycles 1516171819202122232425262728293031323334353637383940 to ensure that amplification occurred in the linear range, and equal starting amounts of each sample were used.
The rAd vector expressing A20 (rAd.A20) was a gift from Dr. V. Dixit (Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA); the control vector expressing β-galactosidase (rAd.β-gal) was a gift from Dr. R. Gerard (Department of Biochemistry, University of Texas, Southwestern Medical Center, Dallas, TX). Islets were infected with rAd vectors immediately after isolation as described previously for other cell types 28. After infection, islets were cultured for an additional 24 h before being used for further experiments. For all experiments (unless otherwise stated), 200 islets were cultured in 500 µl of media in 24-well tissue culture plates.
Expression of A20 protein after rAd.A20 gene transduction in islets was determined by Western blotting using standard techniques. A20 protein expression was detected with a polyclonal A20 antiserum (A20-NT) raised against an NH2 terminus peptide sequence of human A20 (IRERTPEDIFKPTN). Islet viability after viral infection was assessed by staining with propidium iodide (10 µg/ml) and calcein-AM (2 µM; Molecular Probes), then determined by two-color fluorescence microscopy.
Islet cultures were stimulated with recombinant murine IL-1β (10 U/ml) and recombinant rat IFN- (300 U/ml) (R&D Systems) for 40 h. Islets were then harvested, dispersed, fixed in 70% ethanol, and suspended into DNA staining buffer (PBS, pH 7.4, containing 0.1% Triton X-100, 0.1 mM EDTA, 50 µg/ml propidium iodide, 50 µg/ml RNase A). Islet DNA content was analyzed on a FACScanTM using CELLQuestTM acquisition software (Becton Dickson Immunocytometry Systems). Islets with a normal DNA content (
2 N) were scored as viable, whereas islets with a hypodiploid DNA content (<2 N, termed A°) were scored as apoptotic. To exclude debris and apoptotic cell-free fragments, all events with an FL-2 area profile below that of chicken erythrocyte nuclei were excluded from analysis.
To determine the effects of A20 expression on iNOS protein induction, islets were stimulated with IL-1β (10 U/ml) for 24 h. iNOS protein expression was determined by Western blotting using the polyclonal anti-iNOS Ab, N-20 (Santa Cruz).
Culture media were analyzed for NO levels (measured as nitrite) by adding 50 µl of Griess reagent (equal volume of 1% sulfanilamide in 0.1 M HCl and 0.1% N-[-1-naphthyl-ethylenediamine dihydrochloride]) to 50 µl of culture media. Nitrite concentration was determined by spectrophotometry (560 nM) from a standard curve (0–200 µM) derived from NaNO2. NO data are expressed as mean ± SD [nitrite] in µM per 200 islets.
To examine whether NO could directly induce apoptosis, islets were treated for 24 h with the NO donors S-nitrosoglutathione (GSNO) or N-(2-aminoethyl)-N-(2-hydroxy-2-nitrosohydrazino-1,2-ethylenediamine (NONOate) over a range of concentrations (0.001–10 mM). To determine the role of NO in cytokine-induced apoptosis, islets were treated with IL-1β (10 U/ml) and IFN- (300 U/ml) in the presence or absence of the NOS inhibitor L-N5-(1-iminoethyl) ornithine, dihydrochloride (L-NIO) used at the optimal concentration of 500 µM. The extent of islet apoptosis and NO generation was determined as described above.
β-TC3 cells 29 were plated at a density of 1.5 x 106 cells/well into 6-well tissue culture plates and transfected 24 h later using the Lipofectamine-Plus reagent (GIBCO BRL) with 1 µg total DNA. Specifically, β-TC3 cells were transfected with 0.6 µg of the iNOS reporter (pGLH/H2; containing 1,755 bp of the murine iNOS promoter linked to a luciferase gene [30]), a gift of Dr. W.J. Murphy (Wilkinson Laboratory of the Kansas Cancer Institute, University of Kansas Medical Center, Kansas City, KS); 0.3 µg of an expression plasmid containing the human A20 gene (pcDNA3/HA-A20) or the control empty plasmid pcDNA3; and 0.1 µg of a β-gal reporter (driven by the CMV promoter), used to correct for transfection efficiency. 24 h after transfection, cells were stimulated with IL-1β (100 U/ml) for 36 h. These conditions were shown to be optimal in preliminary experiments (data not shown). Luciferase and β-gal activity were assessed as described 27. Data are expressed as relative luciferase activity according to the formula: luciferase light units/β-gal light units x 100.
To determine the effect of A20 overexpression on the transcription factor NF-B, islets (1,000 islets/1 ml media in 24-well tissue culture plates) were stimulated with IL-1β (100 U) for 1 h. Islet nuclei were recovered by an isoosmotic/NP-40 lysis procedure, and nuclear proteins were extracted as described 31. DNA binding reactions were performed by incubating 5 µg of nuclear proteins with 1 µg of poly(dI-dC) and 105 cpm of radiolabeled NF-B consensus oligonucleotide, 5'-AGT TGA GGG GAC TTT CCC AGG C-3' (Promega Corp.). For competition assays, 1.75 pmol of either unlabeled NF-B or an unrelated oligonucleotide was added to the reaction mixture. Supershift analysis was conducted by adding 0.1 µg of Ab specific for p50/NF-B1, p65/RelA, Rel-B, c-Rel, or Ets-1 (Santa Cruz) to the reaction 1 h before the addition of radiolabeled oligonucleotide. The DNA binding reactions were resolved on a 6% polyacrylamide gel and analyzed by autoradiography. B Degradation.
The effect of A20 expression on IB protein degradation was determined by Western blot analysis, after treatment with IL-1β (100 U/ml) for 0, 15, and 60 min. IB protein expression was detected using the polyclonal anti-IB Ab, C-20 (Santa Cruz).
All statistical analysis was conducted using the alternate Welch's method.
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
A20 Is Induced in Islets of Langerhans in Response to Inflammatory Stimuli.
We first examined if A20 was expressed constitutively in islets and whether A20 expression could be induced by cytokine stimulation. No or weak constitutive A20 mRNA was detected in rat and human islets as analyzed by reverse transcription (RT)-PCR (Fig. 1, a and b). A20 mRNA was rapidly induced (within 1–2 h) in both rat and human islets after IL-1β stimulation (Fig. 1, a and b). Rat β insulinoma cells (Rin5F) could also be induced to rapidly express A20 mRNA after IL-1β stimulation, indicating that β cells specifically express A20 (Fig. 1 c). The identity of the A20 PCR product was confirmed by sequence analysis (data not shown). Our data demonstrate that A20 is an early response gene in cytokine-activated islets.
|
30:1) led to significant toxicity in our system (data not shown) and hence MOIs in the range of 1–20:1 were used.
|
A20 Overexpression Protects Islets from Cytokine-induced Apoptosis.
Previous work has demonstrated that A20 is an early response gene that protects cells against cytokine-mediated cytotoxicity 2526. The proinflammatory cytokine IL-1β is cytotoxic to β cells and represents a significant mediator of β cell apoptosis in IDDM, especially in combination with IFN- 10. Therefore, we examined whether A20 would protect islets against IL-1β– and IFN-–mediated toxicity. IL-1β and IFN- used at the optimal dose of 10 and 300 U/ml, respectively, induced a significant percentage of apoptosis in rat islets after 40 h in culture (Fig. 3). This percentage (mean ± SD, n = 4 independent experiments) reached 57.58 ± 16.51 and 55.08 ± 18.35% in both noninfected and control rAd.β-gal–infected islets, respectively (P < 0.01, n = 4), as evaluated by FACS® analysis of DNA content (Fig. 3). In contrast, rAd.A20-infected islets were protected from IL-1β– and IFN-–mediated apoptosis; the percentage of apoptosis in these islets was not significantly different (P = 0.714, n = 4) from that observed in non–cytokine-activated control islets (Fig. 3). These data demonstrate that A20 protects islets from cytokine-mediated apoptosis.
|
(Fig. 4). In contrast, NO production in rAd.A20-infected islets was totally suppressed (P < 0.0001, n = 4) compared with noninfected and rAd.β-gal–infected islets and was not significantly different (P = 0.099, n = 4) from background levels observed in non–cytokine-activated groups (Fig. 4). Thus, the percentage of islets undergoing apoptosis for each treatment correlated with their production of NO.
|
–induced Apoptosis Is Mediated by NO. underwent apoptosis and generated high levels of NO (Fig. 5 b). In contrast, islets stimulated with IL-1β and IFN- in the presence of L-NIO were completely protected from apoptosis (P < 0.001, n = 3), and NO generation was suppressed to below background levels (P < 0.01, n = 3; Fig. 5 b). Taken together, these data demonstrate that NO is the central mediator of cytokine-induced islet apoptosis.
|
by itself had little or no effect on NO induction (data not shown).
We examined whether A20 overexpression would modulate the induction of iNOS protein after cytokine stimulation. Noninfected and rAd.β-gal–infected islets expressed high levels of iNOS protein 24 h after activation with IL-1β (Fig. 6 a). These data are in accordance with previous studies demonstrating that in islets, cytokine treatment results in de novo production of iNOS mRNA and protein 34. In contrast, IL-1β–mediated upregulation of iNOS protein was totally suppressed in A20-expressing islets (Fig. 6 a). Accordingly, NO generation after IL-1β stimulation was highly suppressed (90%) in A20-expressing islets compared with the significant NO levels detected in noninfected and rAd.β-gal infected islets (data not shown).
|
It has been established that induction of iNOS mRNA expression by IL-1β is regulated at the transcription level 303435. Therefore, we questioned whether the inhibitory effect of A20 on inos gene upregulation occurred at the level of gene transcription. To address this possibility, β-TC3 cells were cotransfected with a murine iNOS reporter 30 and a human A20 expression plasmid or the control plasmid, pcDNA3. β-TC3 cells were stimulated with IL-1β (100 U/ml) for 36 h after transfection, and luciferase values were calculated as described in Materials and Methods. As shown in Fig. 6 c, IL-1β stimulation resulted in a significant two- to threefold induction of the iNOS reporter in the pcDNA3-transfected β-TC3 cells (mean fold induction ± SD, 2.23 ± 0.747; P < 0.0001, n = 5). In contrast, IL-1β induction of the iNOS reporter in A20-expressing β-TC3 cells was totally suppressed (P < 0.0001, n = 5) to the extent that there was no difference relative to background levels in pcDNA3-transfected β-TC3 cells (P = 0.75, n = 5). Interestingly, A20 overexpression also significantly reduced the basal (nonstimulated) iNOS reporter activity by 
50% (P < 0.005, n = 5) compared with β-TC3 cells transfected with pcDNA3.
A20 Inhibits NF-B Activation at a Level Upstream of IB Degradation.
Our data indicate that A20 can suppress the IL-1β–dependent activation of the inos gene. Previous reports have implicated the transcription factor NF-B as an essential component of this activation 3436. Therefore, we examined whether A20 was suppressing inos transcription via modulation of NF-B activation. To check whether A20 expression was altering NF-B translocation to the nucleus, we performed electrophoretic mobility shift assays (EMSAs) using nuclear extracts isolated from noninfected, rAd.β-gal–, and rAd.A20-infected islets after IL-1β stimulation (Fig. 7 a). A slow migrating complex, binding to an NF-B consensus sequence, was observed in noninfected and rAd.β-gal–infected islets 1 h after stimulation with IL-1β (Fig. 7 a, arrow). In contrast, this complex was not detected in nuclear extracts from rAd.A20-infected islets after IL-1β stimulation. This complex was resolved by supershift analysis to comprise the p50 and p65 NF-B subunits (Fig. 7 b). The fastest migrating band was not affected by any treatment and most likely represents a nonspecific protein interaction. These data show that A20 inhibits, in islets, the translocation of NF-B to the nucleus.
|
B, IB, in response to IL-1β is a prerequisite for NF-B translocation 3738. We next examined whether expression of A20 in islets was affecting the degradation of IB in response to IL-1β. Western blot analysis of cytoplasmic extracts from noninfected and rAd.β-gal–infected islets showed that IB was rapidly degraded within 15 min after IL-1β stimulation (Fig. 7 c). In contrast, expression of A20 in islets totally inhibited the degradation of IB observed after IL-1β stimulation (Fig. 7 c). To ascertain that expression of A20 in islets was not simply delaying IB degradation, we examined IB levels at several time points after IL-1β stimulation (e.g., 20, 30, 45, and 60 min). No IB degradation was observed at any of these time points (Fig. 7 c, and data not shown). |
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Little is currently known about the expression of cytoprotective genes in β cells and the molecular basis of their susceptibility to apoptosis. Recent reports demonstrated that islets constitutively express the prototypic antiapoptotic molecule Bcl-2, the stress-related heat-shock protein HSP70, and several free radical scavenging enzymes such as manganese superoxide dismutase (MnSOD) and catalase 40. Despite expression of these proteins, β cells remain particularly sensitive to apoptosis when challenged with additional cellular stress 41. This is in part explained by their lower expression of constitutive cytoprotective genes 41. With this perspective in mind, we questioned whether islets are able to mount a protective response to inflammation. In this report, we examined whether β cells could be induced to express the antiapoptotic protein A20. A20 was originally described as a TNF-–inducible 7-Zn finger protein in endothelial cells 25. Its expression can also be induced in response to a variety of inflammatory stimuli, such as LPS, CD40 ligation, the LMP1 protein of EBV, and the Tax protein of HIV 42434445. The rapid induction of A20 mRNA by these diverse stimuli requires the activation of the transcription factor NF-B. Two B binding elements map within the A20 promoter and are essential for its expression 46. Here we show that expression of A20 is rapidly induced in β cells in response to IL-1β. This is the first report showing the induced expression of the antiapoptotic gene A20 in β cells. Further, our data show that IL-1β induces the activation of NF-B in islets, which concurs with its ability to upregulate the expression of A20. The rapid kinetics of A20 expression in islets suggests that, as in endothelial cells, it may be a component of their physiological protective response to injury 47.
Having established that A20 is a rapid response gene in β cells, we examined whether A20 maintained its antiapoptotic function in islets. Expression of A20 in islets by means of an rAd protects them from apoptosis induced by IL-1β and IFN-. The protective effect of A20 against IL-1β– and IFN-–induced apoptosis is critical given the central role of IL-1β in β cell dysfunction and destruction during IDDM 948. IL-1β inhibits glucose-dependent insulin secretion, impairs glucokinase synthesis, and induces cell death by apoptosis 4950. Inhibition of IL-1β using neutralizing mAbs prevents diabetes progression in NOD mice 51. The pathway by which IL-1β mediates β cell destruction and toxicity has recently been clarified. IL-1β is produced by activated resident macrophages within the islets 48215253. Once produced, IL-1β acts directly and selectively upon β cells to induce iNOS, leading to the production of high and sustained levels of NO and to a lesser extent superoxide 1254. NO directly induces apoptosis of β cells and is the mediator of the multiple toxic effects of IL-1β on β cells 555657. We confirmed the apoptotic potential of NO in our system with the NO donors GSNO and NONOate, which rapidly induced apoptosis of rat islets. Furthermore, the addition of the NOS inhibitor L-NIO to cytokine-activated islets prevented both NO production and apoptosis. These data demonstrate that endogenously generated NO is the mediator of cytokine-induced islet apoptosis in our system.
The central role of NO in cytokine-mediated β cell toxicity prompted us to examine whether the protective effect of A20 in islets was associated with modulation of NO levels. We found that expression of A20 in islets abrogated NO production in response to cytokines. Taken together with our data showing that pharmacologic suppression of NO production also protects from cytokine-induced apoptosis, these data establish the suppression of NO production as one mechanism by which A20 protects islets 58. The suppression of NO production by A20 could also impact on T cell–dependent β cell destruction. Indeed, NO facilitates T cell–dependent killing via upregulation of Fas on human islets 1559. Ongoing work in our laboratory is aiming at determining whether expression of A20 in islets will also protect β cells against T cell–mediated cytotoxicity via the perforin/granzyme or the Fas/FasL pathway.
The mechanism by which A20 suppresses cytokine-induced NO production is shown to be via inhibition of IL-1β–induced iNOS mRNA and protein expression. Expression of iNOS protein in islets is regulated by de novo transcription of the inos gene 303435. We reasoned that the absence of iNOS protein and mRNA after cytokine stimulation points to a blockade at the level of transcription. Indeed, we found that A20 suppresses IL-1β–induced activation of a murine iNOS reporter, indicating that A20 was regulating iNOS expression at the level of gene transcription. Since NF-B is the major transcription factor responsible for de novo activation of inos transcription by inflammatory stimuli including IL-1β, we examined the effect of A20 overexpression on NF-B activation 60. We found that A20 suppresses the activation of the transcription factor NF-B in islets. Expression of other NF-B–dependent proinflammatory genes involved in IDDM, such as intercellular adhesion molecule 1 (ICAM-1), are also expected to be blunted by A20, thereby adding to the beneficial effect of A20 as a gene therapy tool 6162. We have previously shown that A20 has a dual antiapoptotic and antiinflammatory function in primary endothelial cells 28. This dual function is clearly maintained in islets, suggesting that inhibition of NF-B activation by A20 is an important component of the natural physiological role of A20. The effect of A20 seems specific to NF-B and is not a result of a toxic effect of A20 on the transcription machinery. Indeed, A20 overexpression had no effect on IFN-–mediated MHC class I upregulation (data not shown), a process requiring the activation of the transcription factors signal transducer and activator of transcription 1 (STAT-1) and IFN regulatory factor 1 (IRF-1) 6364.
NF-B is a ubiquitous transcription factor constitutively expressed in the cytoplasm in an inactive form associated to an inhibitory protein termed IB 3738. Cellular activation by inflammatory stimuli such as IL-1β results in the phosphorylation and subsequent degradation of IB, thus allowing NF-B to translocate into the nucleus and activate target genes such as inos 3738. Therefore, we examined what effect A20 had on IB degradation. Our data demonstrate that A20 interferes with NF-B activation at a level upstream of the kinase cascade leading to IB degradation, as no IB degradation was observed in A20-expressing islets after IL-1β stimulation. Several potential targets for A20 within the IL-1β–stimulated cascade leading to NF-B activation have been reported. Yeast double hybrid studies have demonstrated that A20 interacts with TNF receptor–associated factor (TRAF)-1/2, TRAF-6, and the adapter proteins 14-3-3 656666a. The interaction of A20 with 14-3-3 proteins is interesting given the potential involvement of 14-3-3 (via their interaction with c-raf) in multiple signaling cascades leading to NF-B activation 67. In addition, IL-1β–mediated activation of NF-B requires TRAF-6 and the IL-1 receptor–associated kinase IRAK 686970. Therefore, TRAF-6 is also a likely point where A20 intercepts the IL-1β signaling cascade. Interactions between A20 and TRAF-6 or 14-3-3 in islets are currently being studied in our laboratory.
In addition, data in the literature show that IL-1β–induced NF-B activation and inos mRNA induction can be suppressed in islets by antioxidants such as pyrrolidine dithiocarbamate (PDTC) 34. Moreover, NF-B is a redox-sensitive transcription factor, as indicated by the fact that NF-B activation can be induced by H2O2 or, conversely, NF-B nuclear translocation is blocked by antioxidants such as PDTC 7172. The potential for A20 to interfere at the oxidative step in NF-B activation is currently being tested. Interestingly, several studies have addressed the protective potential of antioxidants in islets by overexpressing free radical scavenging enzymes 41737475. The overexpression of MnSOD in an engineered β cell resulted in selective protection from IL-1β–induced cytotoxicity as well as a reduction in cytokine-induced NO generation 75. In addition, transgenic expression of the antioxidant thioredoxin in β cells of NOD mice reduced the incidence of spontaneous diabetes and protected from streptozotocin-induced diabetes 76. Interestingly, thioredoxin has been shown to inhibit NF-B by interfering with a redox-sensitive step required for its activation 7778. Thus, in the model of Hotta et al. 76, the protective effect of thioredoxin may involve inhibition of NF-B activation, given the role of NF-kB activation in NO generation and islet destruction 365479. Together, these data illustrate a novel concept whereby protection of the target (in this case, β cells) would offer a potent therapeutic strategy to inhibit disease occurrence even in the presence of the effector mechanisms (cellular and soluble mediators). This approach might constitute an alternative to systemic modulation of the immune system as currently practiced using diverse immunosuppressants, such as costimulation blockade 80818283. Along with this approach, other antiapoptotic genes such as bcl-2 have been proposed as gene therapy tools to protect islets from cytokine-mediated apoptosis. Expression of Bcl-2 in a murine β cell line did provide modest protection from cytokine-mediated apoptosis 8485. Interestingly, bcl genes have, like A20, antiinflammatory properties through blockade of transcription factors, such as NF-B in endothelial cells 868788. We are currently testing whether they maintain this dual function in islets and could synergize with A20 to protect β cells. However, in contrast to A20, Bcl-2 is expressed constitutively in islets and is not induced upon cytokine activation (data not shown). We propose that constitutively expressed antiapoptotic proteins such as Bcl-2 may function to protect cells from baseline cellular stress, whereas induced cytoprotective proteins such as A20 protect cells from greater stress caused by inflammatory reactions 47. We suggest that A20 could be a more relevant gene therapy candidate for protection of β cells against the additional stress encountered in the setting of transplantation and autoimmunity. Future experiments will determine the efficacy of A20 in both islet transplant and autoimmune diabetes models.
|
Acknowledgments |
|---|
This research is supported by National Institutes of Health grant 1PO1DK53087/01 awarded to C. Ferran and in part by the Juvenile Diabetes Foundation International through the Juvenile Diabetes Foundation Center for Islet Transplantation at Harvard Medical School. This is manuscript no. 791 from our laboratories.
Submitted: 4 February 1999
Revised: 2 August 1999
Accepted: 6 August 1999
B, inhibitor of NF-B; iNOS, inducible NO synthase; L-NIO, l-N5-(1-iminoethyl) ornithine, dihydrochloride; MnSOD, manganese superoxide dismutase; MOI, multiplicity of infection; NF-B, nuclear factor B; NO, nitric oxide; NOD, nonobese diabetic; NONOate, N-(2-aminoethyl)-N-(2-hydroxy-2-nitrosohydrazino-1,2-ethylenediamine; rAd, recombinant adenovirus; RT, reverse transcription; TRAF, TNF receptor–associated factor Shane T. Grey, Immunobiology Research Center, Harvard Medical School, Beth Israel Deaconess Medical Center, 99 Brookline Ave., Boston, MA 02215. Phone: 617-632-0859; Fax: 617-632-0880; E-mail: sgrey@caregroup.harvard.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Benoist C. & Mathis D.. Cell death mediators in autoimmune diabetes—no shortage of suspects, Cell., 89, 1997, 1–3.[Medline]
Andre I., Gonzalez A., Wang B., Katz J., Benoist C. & Mathis D.. Checkpoints in the progression of autoimmune diseaselessons from diabetes models, Proc. Natl. Acad. Sci. USA., 93, 1996, 2260–2263.
Delovitch T.L. & Singh B.. The nonobese diabetic mouse as a model of autoimmune diabetesimmune dysregulation gets the NOD, Immunity., 7, 1997, 727–738.[Medline]
Cameron M.J., Meagher C. & Delovitch T.L.. Failure in immune regulation begets IDDM in NOD mice, Diab. Metab. Rev., 14, 1998, 177–185.[Medline]
Mauricio D. & Mandrup-Poulsen T.. Apoptosis and the pathogenesis of IDDMa question of life and death, Diabetes., 47, 1998, 1537–1543.[Abstract]
Kurrer M.O., Pakala S.V., Hanson H.L. & Katz J.D.. Beta cell apoptosis in T cell-mediated autoimmune diabetes, Proc. Natl. Acad. Sci. USA., 94, 1997, 213–218.
Kagi D., Odermatt B., Seiler P., Zinkernagel R.M., Mak T.W. & Hengartner H.. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice, J. Exp. Med., 186, 1997, 989–997.
Chervonsky A.V., Wang Y., Wong F.S., Visintin I., Flavell R.A., Janeway C.A. Jr. & Matis L.A.. The role of Fas in autoimmune diabetes, Cell., 89, 1997, 17–24.[Medline]
Arnush M., Heitmeier M.R., Scarim A.L., Marino M.H., Manning P.T. & Corbett J.A.. IL-1 produced and released endogenously within human islets inhibits beta cell function, J. Clin. Invest., 102, 1998, 516–526.[Medline]
Heitmeier M.R., Scarim A.L. & Corbett J.A.. Interferon- increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1, J. Biol. Chem., 272, 1997, 13697–13704.
Xie Q. & Nathan C.. The high-output nitric oxide pathwayrole and regulation, J. Leukocyte Biol., 56, 1994, 576–582.[Abstract]
Xia Y., Roman L.J., Masters B.S. & Zweier J.L.. Inducible nitric-oxide synthase generates superoxide from the reductase domain, J. Biol. Chem., 273, 1998, 22635–22639.
Kaneto H., Fujii J., Seo H.G., Suzuki K., Matsuoka T., Nakamura M., Tatsumi H., Yamasaki Y., Kamada T. & Taniguchi N.. Apoptotic cell death triggered by nitric oxide in pancreatic β-cells, Diabetes., 44, 1995, 733–738.[Abstract]
Ankarcrona M., Dypbukt J.M., Brune B. & Nicotera P.. Interleukin-1β-induced nitric oxide production activates apoptosis in pancreatic RINm5F cells, Exp. Cell Res., 213, 1994, 172–177.[Medline]
Stassi G., Maria R.D., Trucco G., Rudert W., Testi R., Galluzzo A., Giordano C. & Trucco M.. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus, J. Exp. Med., 186, 1997, 1193–1200.
Takamura T., Kato I., Kimura N., Nakazawa T., Yonekura H., Takasawa S. & Okamoto H.. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic β cells develop insulin-dependent diabetes without insulitis, J. Biol. Chem., 273, 1998, 2493–2496.
Reckard C.R., Stuart F.P. & Schulak J.A.. Immunologic comparisons of isolated pancreatic islet and whole-organ allografts, Transplant. Proc., 11, 1979, 563–566.[Medline]
Ballinger W.. ProceedingsIsolation and transplantation of islets of Langerhans in rat and monkey, Ann. R. Coll. Surg. Engl., 58, 1976, 327–330.[Medline]
Lacy P.E. & Davie J.M.. Transplantation of pancreatic islets, Annu. Rev. Immunol., 2, 1984, 183–198.[Medline]
Weir G.C. & Bonner-Weir S.. Islet transplantation as a treatment for diabetes, J. Am. Optom. Assoc., 69, 1998, 727–732.[Medline]
Bottino R., Fernandez L.A., Ricordi C., Lehmann R., Tsan M.F., Oliver R. & Inverardi L.. Transplantation of allogeneic islets of Langerhans in the rat livereffects of macrophage depletion on graft survival and microenvironment activation, Diabetes., 47, 1998, 316–323.[Abstract]
Davalli A.M., Scaglia L., Zangen D.H., Hollister J., Bonner-Weir S. & Weir G.C.. Early changes in syngeneic islet graftseffect of recipient's metabolic control on graft outcome, Transplant. Proc., 27, 1995, 3238–3239.[Medline]
Davalli A.M., Scaglia L., Zangen D.H., Hollister J., Bonner-Weir S. & Weir G.C.. Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function, Diabetes., 45, 1996, 1161–1167.[Abstract]
Efrat S.. Prospects for gene therapy of insulin-dependent diabetes mellitus, Diabetologia., 41, 1998, 1401–1409.[Medline]
Opipari A.J., Boguski M.S. & Dixit V.M.. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein, J. Biol. Chem., 265, 1990, 14705–14708.
Opipari A.J., Hu H.M., Yabkowitz R. & Dixit V.M.. The A20 zinc finger protein protects cells from TNF cytotoxicity, J. Biol. Chem., 267, 1992, 12424–12427.
Cooper J.T., Stroka D.M., Brostjan C., Palmetshofer A., Bach F.H. & Ferran C.. A20 blocks endothelial cell activation through a NF-B-dependent mechanism, J. Biol. Chem., 271, 1996, 18068–18073.
Ferran C., Stroka D.M., Badrichani A.Z., Cooper J.T., Wrighton C.J., Soares M., Grey S.T. & Bach F.H.. A20 inhibits NF-B activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis, Blood., 91, 1998, 2249–2258.
D'Ambra R., Surana M., Efrat S., Starr R.G. & Fleischer N.. Regulation of insulin secretion from β-cell lines derived from transgenic mice insulinomas resembles that of normal β-cells, Endocrinology., 126, 1990, 2815–2822.
Lowenstein C.J., Alley E.W., Raval P., Snowman A.M., Snyder S.H., Russell S.W. & Murphy W.J.. Macrophage nitric oxide synthase genetwo upstream regions mediate induction by interferon and lipopolysaccharide, Proc. Natl. Acad. Sci. USA., 90, 1993, 9730–9734.
Dyer R.B. & Herzog N.K.. Isolation of intact nuclei for nuclear extract preparation from a fragile B-lymphocyte cell line, Biotechniques., 19, 1995, 192–195.[Medline]
O'Brien B.A., Harmon B.V., Cameron D.P. & Allan D.J.. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model, J. Pathol., 178, 1996, 176–181.[Medline]
Corbett J.A., Lancaster J.R. Jr., Sweetland M.A. & McDaniel M.L.. Interleukin-1β-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1β-induced inhibition of insulin secretion, J. Biol. Chem., 266, 1991, 21351–21354.
Kwon G., Corbett J.A., Rodi C.P., Sullivan P. & McDaniel M.L.. Interleukin-1β-induced nitric oxide synthase expression by rat pancreatic β-cellsevidence for the involvement of nuclear factor B in the signaling mechanism, Endocrinology., 136, 1995, 4790–4795.[Abstract]
Lorsbach R.B., Murphy W.J., Lowenstein C.J., Snyder S.H. & Russell S.W.. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon- and lipopolysaccharide, J. Biol. Chem., 268, 1993, 1908–1913.
Taylor B.S., de Vera M.E., Ganster R.W., Wang Q., Shapiro R.A., Morris S.M. Jr., Billiar T.R. & Geller D.A.. Multiple NF-B enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene, J. Biol. Chem., 24, 1998, 15148–15156.[Medline]
Baeuerle P.A. & Baltimore D.. IBa specific inhibitor of the NF-B transcription factor, Science., 242, 1988, 540–546.
Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S. & Baeuerle P.A.. Phosphorylation of human IB- on serines 32 and 36 controls IB- proteolysis and NF-B activation in response to diverse stimuli, EMBO (Eur. Mol. Biol. Organ.) J., 14, 1995, 2876–2883.[Medline]
Efrat S., Fejer G., Brownlee M. & Horwitz M.S.. Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes, Proc. Natl. Acad. Sci. USA., 92, 1995, 6947–6951.
Welsh N., Margulis B., Borg L.A., Wiklund H.J., Saldeen J., Flodstrom M., Mello M.A., Andersson A., Pipeleers D.G. & Hellerstrom C.. Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic isletsimplications for the pathogenesis of insulin-dependent diabetes mellitus, Mol. Med., 1, 1995, 806–820.[Medline]
Tiedge M., Lortz S., Drinkgern J. & Lenzen S.. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells, Diabetes., 46, 1997, 1733–1742.[Abstract]
Hu X., Yee E., Harlan J.M., Wong F. & Karsan A.. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells, Blood., 92, 1998, 2759–2765.
Sarma V., Lin Z., Clark L., Rust B.M., Tewari M., Noelle R.J. & Dixit V.M.. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis, J. Biol. Chem., 270, 1995, 12343–12346.
Laherty C.D., Hu H.M., Opipari A.W., Wang F. & Dixit V.M.. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating NF-B, J. Biol. Chem., 267, 1992, 24157–24160.
Laherty C.D., Perkins N.D. & Dixit V.M.. Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor B, J. Biol. Chem., 268, 1993, 5032–5039.
Krikos A., Laherty C.D. & Dixit V.M.. Transcriptional activation of the tumor necrosis factor -inducible zinc finger protein, A20, is mediated by B elements, J. Biol. Chem., 267, 1992, 17971–17976.
Bach F.H., Hancock W.W. & Ferran C.. Protective genes expressed in endothelial cellsa regulatory response to injury, Immunol. Today., 18, 1997, 483–486.[Medline]
Arnush M., Scarim A.L., Heitmeier M.R., Kelly C.B. & Corbett J.A.. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes, J. Immunol., 160, 1998, 2684–2691.
Ling Z., Chen M.C., Smismans A., Pavlovic D., Schuit F., Eizirik D.L. & Pipeleers D.G.. Intercellular differences in interleukin 1β-induced suppression of insulin synthesis and stimulation of noninsulin protein synthesis by rat pancreatic β-cells, Endocrinology., 139, 1998, 1540–1545.
Ma Z., Landt M., Bohrer A., Ramanadham S., Kipnis D.M. & Turk J.. Interleukin-1 reduces the glycolytic utilization of glucose by pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism, J. Biol. Chem., 272, 1997, 17827–17835.
Cailleau C., Diu-Hercend A., Ruuth E., Westwood R. & Carnaud C.. Treatment with neutralizing antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice, Diabetes., 46, 1997, 937–940.[Abstract]
Jun H.S., Santamaria P., Lim H.W., Zhang M.L. & Yoon J.W.. Absolute requirement of macrophages for the development and activation of β-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice, Diabetes., 48, 1999, 34–42.[Abstract]
Jun H.S., Yoon C.S., Zbytnuik L., van Rooijen N. & Yoon J.W.. The role of macrophages in T cell–mediated autoimmune diabetes in nonobese diabetic mice, J. Exp. Med., 189, 1999, 347–358.
Rabinovitch A., Suarez-Pinzon W.L., Sorensen O. & Bleackley R.C.. Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic miceidentification of iNOS-expressing cells and relationships to cytokines expressed in the islets, Endocrinology., 137, 1996, 2093–2099.[Abstract]
Corbett J.A., Sweetland M.A., Wang J.L., Lancaster J.R. Jr. & McDaniel M.L.. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans, Proc. Natl. Acad. Sci. USA., 90, 1993, 1731–1735.
Delaney C.A., Pavlovic D., Hoorens A., Pipeleers D.G. & Eizirik D.L.. Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells, Endocrinology., 138, 1997, 2610–2614.
Wilson G.L., Patton N.J. & LeDoux S.P.. Mitochondrial DNA in beta-cells is a sensitive target for damage by nitric oxide, Diabetes., 46, 1997, 1291–1295.[Abstract]
Corbett J.A. & McDaniel M.L.. Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic interventions in IDDM, Diabetes., 41, 1992, 897–903.[Abstract]
Loweth A.C., Williams G.T., James R.F., Scarpello J.H. & Morgan N.G.. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1β and Fas ligation, Diabetes., 47, 1998, 727–732.[Abstract]
Xie Q.W., Kashiwabara Y. & Nathan C.. Role of transcription factor NF-B/Rel in induction of nitric oxide synthase, J. Biol. Chem., 269, 1994, 4705–4708.
Yang X.D., Michie S.A., Mebius R.E., Tisch R., Weissman I. & McDevitt H.O.. The role of cell adhesion molecules in the development of IDDMimplications for pathogenesis and therapy, Diabetes., 45, 1996, 705–710.[Abstract]
Zeng Y., Gage A., Montag A., Rothlein R., Thistlethwaite J. & Bluestone J.. Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies, Transplantation., 58, 1994, 681–689.[Medline]
Gao J., Morrison D.C., Parmely T.J., Russell S.W. & Murphy W.J.. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon- and lipopolysaccharide, J. Biol. Chem., 272, 1997, 1226–1230.
Martin E., Nathan C. & Xie Q.W.. Role of interferon regulatory factor 1 in induction of nitric oxide synthase, J. Exp. Med., 180, 1994, 977–984.
Yeong-Song H., Rothe M. & Goeddel D.V.. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF-1/TRAF-2 and inhibits NF-B activation, Proc. Natl. Acad. Sci. USA., 93, 1996, 6721–6725.
Vincenz C. & Dixit V.M.. 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules, J. Biol. Chem., 271, 1996, 20029–20034.
Heyninck K. & Beyaert R.. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-D activation at the level of TRAF6, FEBS Lett., 442, 1999, 147–150.[Medline]
Tzivion G., Luo Z. & Avruch J.. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity, Nature., 394, 1998, 88–92.[Medline]
Cao Z., Henzel W.J. & Gao X.. IRAKa kinase associated with the interleukin-1 receptor, Science., 271, 1996, 1128–1131.[Abstract]
Cao Z., Xiong J., Takeuchi M., Kurama T. & Goeddel D.V.. TRAF6 is a signal transducer for interleukin-1, Nature., 383, 1996, 443–446.[Medline]
Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., Morony S., Capparelli C., Van G. & Kaufman S.. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, Genes Dev., 13, 1999, 1015–1024.
Schreck R., Rieber P. & Baeuerle P.A.. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-B transcription factor and HIV-1, EMBO (Eur. Mol. Biol. Organ.) J., 10, 1991, 2247–2258.[Medline]
Ferran C., Millan M.T., Csizmadia V., Cooper J.T., Brostjan C., Bach F.H. & Winkler H.. Inhibition of NF-B by pyrrolidine dithiocarbamate blocks endothelial cell activation, Biochem. Biophys. Res. Commun., 214, 1995, 212–223.[Medline]
Kubisch H.M., Wang J., Bray T.M. & Phillips J.P.. Targeted overexpression of Cu/Zn superoxide dismutase protects pancreatic β-cells against oxidative stress, Diabetes., 46, 1997, 1563–1566.[Abstract]
Benhamou P.Y., Moriscot C., Richard M.J., Beatrix O., Badet L., Pattou F., Kerr-Conte J., Chroboczek J., Lemarchand P. & Halimi S.. Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets, Diabetologia., 41, 1998, 1093–1100.[Medline]
Hohmeier H.E., Thigpen A., Tran V.V., Davis R. & Newgard C.B.. Stable expression of manganese superoxide dismutase (MnSOD) in insulinoma cells prevents IL-1β–induced cytotoxicity and reduces nitric oxide production, J. Clin. Invest., 101, 1998, 1811–1820.[Medline]
Hotta M., Tashiro F., Ikegami H., Niwa H., Ogihara T., Yodoi J. & Miyazaki J.. Pancreatic β cell–specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes, J. Exp. Med., 188, 1998, 1445–1451.
Jin D.Y., Chae H.Z., Rhee S.G. & Jeang K.T.. Regulatory role for a novel human thioredoxin peroxidase in NF-B activation, J. Biol. Chem., 272, 1997, 30952–30961.
Kim I.Y. & Stadtman T.C.. Inhibition of NF-B DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment, Proc. Natl. Acad. Sci. USA., 94, 1997, 12904–12907.
O'Brien B.A., Harmon B.V., Cameron D.P. & Allan D.J.. Apoptosis is the mode of β-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse, Diabetes., 46, 1997, 750–757.[Abstract]
Lenschow D.J., Zeng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., Linsley P.S. & Bluestone J.A.. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig, Science., 257, 1992, 789–792.
Benhamou P.Y., Moriscot C., Badet L. & Halimi S.. Strategies for graft immunomodulation in islet transplantation, Diab. Metab., 24, 1998, 215–224.[Medline]
Kendall D.M. & Robertson R.P.. Pancreas and islet transplantation in humans, Diab. Metab., 22, 1996, 157–163.[Medline]
Stratta R.J.. Immunosuppression in pancreas transplantationprogress, problems and perspective, Transpl. Immunol., 6, 1998, 69–77.[Medline]
Iwahashi H., Hanafusa T., Eguchi Y., Nakajima H., Miyagawa J., Itoh N., Tomita K., Namba M., Kuwajima M. & Noguchi T.. Cytokine-induced apoptotic cell death in a mouse pancreatic β-cell lineinhibition by Bcl-2, Diabetologia., 39, 1996, 530–536.[Medline]
Liu Y., Rabinovitch A., Suarez-Pinzon W., Muhkerjee B., Brownlee M., Edelstein D. & Federoff H.J.. Expression of the bcl-2 gene from a defective HSV-1 amplicon vector protects pancreatic β-cells from apoptosis, Hum. Gene Ther., 7, 1996, 1719–1726.[Medline]
Shibasaki F., Kondo E., Akagi T. & McKeon F.. Suppression of signaling through transcription factor NF-AT by interactions between calcineurin and Bcl-2, Nature., 386, 1997, 728–731.[Medline]
Stroka D.M., Badrichani A.Z., Bach F.H. & Ferran C.. Overexpression of A1, an NF-B-inducible anti-apoptotic bcl gene, inhibits endothelial cell activation, Blood., 93, 1999, 3803–3810.
Badrichani A.Z., Stroka D.M., Bilbao G., Curiel D.T., Bach F.H. & Ferran C.. Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-B, J. Clin. Invest., 103, 1999, 543–553.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|
